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Abstract
Background:  Recent rodent studies reported that antidepressant treatments affect the
expression of brain-derived neurotrophic factor (BDNF) mRNA in a way that is dependent on
treatment duration, by selective modulation of different BDNF transcripts. However, no data are
available for the human BDNF gene. We studied the effect of different antidepressants on BDNF
mRNA expression in human neuroblastoma SH-SY5Y cells.
Results:  Cultured cells were treated with the antidepressants fluoxetine, reboxetine and
desipramine for different time lengths (6, 24, 48 hours). Expression of total BDNF mRNA was
analyzed by reverse transcription PCR and levels of different BDNF transcripts were detected by
hemi-nested PCR with specific primers.
Short-term treatment (6 hours) with reboxetine or desipramine reduced total BDNF, whereas
long-term treatment (48 hours) significantly increased total BDNF mRNA levels. These changes
were accounted for by differential regulation of BDNF IV and VIa/b transcripts. Fluoxetine showed
no significant effects.
Conclusion: This is the first study showing biphasic changes in the expression of total and specific
BDNF transcripts in human cells following antidepressant treatments. These findings suggest that
biphasic induction of BDNF by antidepressants could be a feature common to rodents and humans
and encourage the use of SH-SY5Y cells as a tool for investigation of drug effects on human genes.
Background
Brain-derived neurotrophic factor (BDNF) has been
implicated in both the pathophysiology and pharmaco-
therapy of depression [1-3]. It has been shown that BDNF
expression and/or function is impaired in major depres-
sion or following stress paradigms, while it is up-regulated
by physical exercise and antidepressants. However, differ-
ent and sometimes conflicting findings have been
reported [2], showing that antidepressants change total
BDNF expression level depending on length of the treat-
ment and time interval following administration. Indeed,
independent investigations showed that short-term anti-
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depressant treatment decreased BDNF expression in
rodents, whereas long-term treatment increased BDNF [4-
6].
The increasing knowledge of BDNF gene in rodents [7,8]
has encouraged the research on the modulation of differ-
ent BDNF transcripts by pharmacological treatments.
Recent studies showed that different drugs, lengths of
treatment and drug/physical exercise combination, as well
as stress paradigms, may selectively influence the tran-
scription of specific BDNF transcripts in rodents [6,9-12].
However, to the best of our knowledge no data are availa-
ble yet on the effect of antidepressants on human BDNF
transcripts [13]. In addition, the gene structure of human
BDNF has been recently revised. Accordingly, the human
BDNF gene contains ten upstream untranslated exons
(numbered I, II, III, IV, V, Vh, VI, VII, VIII, and VIIIh) that
are alternatively spliced to a common downstream exon
IX containing the coding region and the 3' untranslated
region (see Figure 1). Therefore, aim of the present study
was to investigate whether antidepressant treatments of
different time lengths induce changes in the expression of
BDNF gene also in cultured human cells and to assess
whether these modifications could be explained by differ-
ential regulation of BDNF transcripts. Therefore, total
BDNF mRNA and distinct BDNF transcript levels were
measured by semi-quantitative PCR after treatment with
different antidepressant drugs in human neuroblastoma
SH-SY5Y cells.
Experimental Procedures
Cell culture and pharmacological treatment
Human neuroblastoma SH-SY5Y cells were obtained
from Interlab Cell Line Collection (Genova, Italy), at pas-
sage P14; only cells between passages P16 to P25 were
used. Cells were grown in Minimum Essential Medium
(Invitrogen, Carlsbad, CA), containing 10% foetal bovine
serum, 2 mM glutamine and non-essential aminoacids (1
mg/l) in a humidified incubator (95% air, 5% CO2) at
37°C. Cells were treated for 6, 24 and 48 hours before
harvesting (all cells were kept in culture for 3 days total)
with different antidepressants: the selective serotonin
reuptake inhibitor fluoxetine (FLX), the selective nore-
pinephrine reuptake inhibitor reboxetine (RBX) and the
tricyclic antidepressant desipramine (DMI), predomi-
nantly inhibiting norepinephrine reuptake (all 10 μM,
final concentration).
RNA isolation, cDNA synthesis and reverse transcription-PCR for total 
BDNF expression
Cells from twelve independent experiments were lysed
with Trizol (Invitrogen) and total RNA was isolated with
Phase Lock Gel Heavy (Eppendorf, Hamburg, Germany).
RNA purity was confirmed by spectrophotometry (A260/
A280>1.7) and RNA integrity was visualized by agarose gel
electrophoresis. 4 μg of RNA were reverse transcribed
using cloned AMV first-strand synthesis kit (Invitrogen)
and random hexamers. In order to detect total BDNF, PCR
was performed with primers designed on the sequence of
the coding exon, exon IX (exIX fwd and exIX rev3 primers)
(Table 1 and Figure 1): 5 min 95°C, 33 cycles of 95°C for
15 s, 58°C for 10 s and 72°C for 30 s. BDNF exon IX prim-
ers were used in the same reaction tube together with
primers for the housekeeping Ubiquitin C (UBC) gene
[14] (Table 1), in order to co-amplify the target gene and
the internal standard, which did not vary throughout
experiments. The number of cycles and primer concentra-
tions were chosen experimentally in order to fall into the
exponential phases of the amplification reaction. For
semi-quantitative analysis, amplicons were detected by
gel electrophoresis (8% acrylamide, ethidium bromide
staining). Bands were acquired with Bio-Rad GelDoc Sys-
tem (Bio-Rad Laboratories, CA) and intensities were
measured with Quantity One software (Bio-Rad Laborato-
ries). All the PCR amplicons were sequenced and found to
mirror expected sequences for the different transcripts
(not shown). The intensities of the PCR products of BDNF
total mRNA were normalized on the intensity of the
house-keeping gene UBC and then the data were reported
as ratio between treated cells and control cells. For statis-
tical analysis two-way analysis of variance (ANOVA) was
performed followed by Bonferroni post-hoc tests.
RNA isolation, cDNA synthesis and reverse transcription-PCR for 
BDNF isoforms
RNA was extracted as above from cells of six independent
experiments. 8 μg of RNA were reverse transcribed using
Schematic representation of human BDNF gene and of primers used Figure 1
Schematic representation of human BDNF gene and of primers used.BMC Neuroscience 2008, 9:61 http://www.biomedcentral.com/1471-2202/9/61
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cloned AMV first-strand synthesis kit (Invitrogen) and 2
pmoles of the BDNF specific primer exIX rev3 (Table 1),
in order to increase the specificity of the reaction. Due to
the low level of some transcripts, semi-quantitative hemi-
nested PCR was used to detect specific BDNF exons [15].
Figure 1 and Tables 1 and 2 show human BDNF tran-
scripts and primers used. To preamplify transcripts, a first
PCR was performed (5 min 95°C, 15 cycles of 95°C for 15
s, 58°C for 10 s and 72°C for 30 s) using exIX rev2 and
forward primers specific for individual BDNF transcripts.
The second PCR was carried out with 2 μl of the first PCR
products, using the reverse primer exIX rev1 and specific
forward primers. The number of cycles and primer con-
centrations were chosen experimentally in order to fall
into the exponential phases of the amplification reaction
(between 20 and 30 cycles). UBC was used as internal
control. Measurement of band intensities, normalization
of data and statistical analysis were as described for total
BDNF.
Results
In order to characterize the effects of different antidepres-
sants on total human BDNF mRNA expression, SH-SY5Y
neuroblastoma cells were treated with FLX, RBX or DMI
for 6 h (to assess the effects of short-term treatments), 24
or 48 hours, as in recent studies assessing the long-term
effects of antidepressants in cultured cells [16,17]. With
regard to the antidepressant concentration in the cell
medium, several studies have found that therapeutic
plasma levels of these drugs in humans under chronic
treatment are in the low micromolar range. However, it
has been also shown that their concentrations in brain tis-
sue can be as much as 20 times higher compared to
plasma levels [18,19]. Moreover, it has been reported that
brain concentrations of different antidepressants adminis-
tered systemically at different doses were similar, without
a clear correlation with either treatment dose or treatment
duration [19]. Therefore, in order to expose the neurob-
lastoma cells to a drug concentration as close as possible
to those reached in brain tissue, we chose to treat cultured
SH-SY5Y cells with 10 μM FLX, RBX or DMI in our exper-
iments.
Two-way ANOVA analysis of total BDNF mRNA expres-
sion showed significant effects of time (F3,193 = 25.04; p <
.0001), drug (F2,193  = 4.60; p < .05) and interaction
between the two variables (F6,193 = 4.48; p < .001). In par-
ticular, RBX and DMI exerted a biphasic effect on BDNF
mRNA: BDNF mRNA expression was reduced after 6
hours treatment with RBX or DMI, returned to basal level
at 24 hours and was significantly increased after 48 hours
(Fig. 2A). FLX did not show any significant effect at any
time.
The BDNF transcript expression pattern in SH-SY5Y cells
is similar to that of human cortical tissue [20]: according
to a recent nomenclature of BDNF gene [13], BDNF IV
and VI are the most highly expressed transcripts, repre-
senting over 80% of the total BDNF. Therefore, in order to
evaluate if the modifications induced in total BDNF
mRNA levels by antidepressants were due to alterations in
the main BDNF transcripts, the expression profile of
BDNF IV and VIa/b transcripts were analyzed. Cells were
treated with FLX, DMI or RBX for 6 hours or 48 hours,
times at which expression of total BDNF mRNA was
changed after antidepressants (Fig. 2A), and BDNF tran-
script expression level was detected with semi-quantita-
tive hemi-nested PCR. Two way ANOVA showed
significant effects of time (F2,144 = 37,42; p < .0001), drug
(F2,144 = 23,39; p < .0001) and time/drug interaction
(F4,144 = 26,94; p < .0001) for BDNF IV transcript: BDNF
Table 1: Sequences of primers used for RT-PCR.
Primers Sequence
UBC fwd atttgggtcgcggttcttg
exI fwd cacttgagtctccaggacagc
exII fwd caacggatttgtccgaggtgg
exIII fwd atgcctcactgagcccagttcc
exIV fwd cggagcagctgccttgatgg
exVIa/b fwd ctggagccagaatcggaacc
exVII fwd aacccacatctctacccatcc
exVIb-IXbd fwd ggaagaaggagaacttgaagc
exIX fwd actctggagagcgtgaatgg
UBC rev tgccttgacattctcgatggt
exIX rev1 atccaacagctcttctatcacg
exIX rev2 atactgtcacacacgctcagc
exIX rev3 cgtagaagtattgcttcagttgg
Table 2: Human BDNF transcripts and specific primers used for RT-PCR.
Transcript Accession number Primers Product (bp)
BDNF I EF689021.1 exI fwd/exIX rev1 269
BDNF II EF674517.1; EF674518.1; EF674519.1 exII fwd/exIX rev1 301
BDNF III EF674520.1 exIII fwd/exIX rev1 254
BDNF IV EF674521.1 exIV fwd/exIX rev1 283
BDNF VIa/b EF689014.1; EF689015.1 exVIa/b fwd/exIX rev1 306
BDNF VIb-IXbd EF689016.1 exVIb-IXbd fwd/exIX rev1 296
BDNF VIIa/b EF689017.1; EF689018.1 exVII fwd/exIX rev1 285BMC Neuroscience 2008, 9:61 http://www.biomedcentral.com/1471-2202/9/61
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IV was significantly reduced after 6 hours and significantly
increased after 48 h of RBX or DMI (Fig. 2B). FLX showed
no effect. Two way ANOVA of BDNF VIa/b (Fig. 2C)
showed a significant effect of time (F2,107 = 7,19; p < .05)
and of time/drug interaction (F4,107 = 7,53; p < .0001).
Post-hoc comparisons showed a significant reduction of
BDNF VIa/b after 6 hours of RBX and no effects after 48
hours (Fig. 2C). In addition, we analyzed the expression
of the low-level BDNF transcripts, BDNF I, II, VIb-IXbd
and VIIa/b; all drug treatments did not change the expres-
sion of the transcripts (data not shown). BDNF III was
undetectable; expression of exons V, Vh, VIII and VIIIh
was not measured because, when the present work was
completed, the new nomenclature was not yet published
[13].
Discussion
To the best of our knowledge, this is the first study analyz-
ing the effect of antidepressant treatments on the expres-
sion of BDNF transcripts in cells of human origin.
Previous studies found time-dependent biphasic changes
in the expression of total BDNF induced by antidepres-
sants in rat brain [4-6]. Similarly, we found that in SH-
SY5Y cells RBX and DMI induced biphasic changes in total
BDNF mRNA expression. Indeed, short-term treatment
with both antidepressants significantly reduced, whereas
long-term treatment increased total BDNF mRNA. At the
intermediate time BDNF mRNA levels were similar to
control. FLX did not significantly affect BDNF expression,
likely owing to the absence of the serotonin transporter in
SH-SY5Y cells, which instead express the norepinephrine
transporter [21,22], and the 5-HT2b serotonergic receptor
and the α2c adrenoreceptor [23-26]. Indeed, we could con-
firm the absence of any signal for serotonin transporter
mRNA in SH-SY5Y cells by PCR (not shown). An alterna-
tive explanation could be found in the lack of changes in
BDNF expression after fluoxetine treatment in rodents, as
reported by several studies [9,27-30].
The present results suggest that early reduction of total
BDNF mRNA in SH-SY5Y cells was mainly accounted for
by a reduction of BDNF IV by RBX and DMI administra-
tion, and of BDNF VIa/b by RBX. On the other hand, the
increase in total BDNF mRNA after 48 hours of treatment
appeared to be mainly accounted for by the induction of
BDNF IV by both drugs.
Interestingly, previous studies in rodents have shown a
differential regulation of distinct BDNF transcripts by
antidepressant treatments [6,9,11]. In particular, it has
been shown that chronic defeat stress, a model of depres-
sion, selectively down-regulated in mouse hippocampus
the expression of BDNF III and BDNF IV transcripts (cor-
responding in the present study to BDNF IV and BDNF
VIa/b respectively, according to the new nomenclature of
Effects of antidepressant treatment on expression of total  BDNF mRNA and BDNF transcripts in SH-SY5Y cells Figure 2
Effects of antidepressant treatment on expression of 
total BDNF mRNA and BDNF transcripts in SH-
SY5Y cells. A. Expression of total BDNF mRNA in SH-
SY5Y cells after 6 h, 24 h and 48 h treatment with 10 μM 
fluoxetine (FLX), reboxetine (RBX) or desipramine (DMI), 
relative to untreated cells. Data are expressed as % intensity 
units/mm2 vs. untreated cells (mean ± s.e.m.). Statistics: two-
way ANOVA, Bonferroni post-hoc test vs. untreated cells: *p 
< 0,05 ***p < 0,001 RBX vs. untreated cells; §p < 0,05 §§§p < 
0,001 DMI vs. untreated cells. B. Expression level of BDNF 
IV transcript after 6 h and 48 h treatment with 10 μM FLX, 
RBX or DMI, relative to untreated cells. *p < 0.05 ***p < 
0.001 RBX vs. untreated cells; §§p < 0.01 DMI vs. untreated 
cells. C. Expression level of BDNF VIa/b after treatment as in 
(B). Data and statistics as above. ***p < 0.001 RBX vs. 
untreated cells.BMC Neuroscience 2008, 9:61 http://www.biomedcentral.com/1471-2202/9/61
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BDNF gene), while chronic imipramine treatment
reversed this down-regulation [12].
The underlying molecular mechanisms are at present
unknown; however, recent evidence from several groups
suggest that different signaling mechanisms may be
responsible for the regulation of BDNF transcription [2].
As an example, it has been shown that different BDNF
promoters contain multiple sites for various transcription
factors (i.e. CREB, CaRF), responding to different signal-
ing pathways mainly activated by calcium fluxes (CaM
kinase cascades), by cyclic AMP (cAMP-PKA cascade) and
by neurotrophic factors (MAP-Erk pathway). In this
regard, we have recently reported that chronic administra-
tion of different antidepressants in rats exerts distinct
actions on CREB activation that seem to depend on a dif-
ferential modulation of CaM kinase IV and MAPK-Erk1/2
cascades [31]. Furthermore, we found that the CaM kinase
IV cascade is also involved in the regulation of CREB acti-
vation by the mood stabilizer lithium [32].
Overall, although further studies are needed to clarify the
upstream mechanisms, these results suggest that time-
dependent biphasic changes in the expression of BDNF IV
and VIa/b account for the observed changes induced by
antidepressants in total BDNF mRNA of SH-SY5Y cells.
Validation by quantitative Real-Time PCR is warranted. A
limitation of the present work is that BDNF protein was
not measured; because often mRNA and protein expres-
sion do not correlate, measurement of BDNF protein in
SH-SY5Y after antidepressant treatments is warranted.
Also considering recent reports on the different structure
and regulation between rodent and human BDNF gene
[7,13], SH-SY5Y cells could provide a useful tool to screen
the effects of different psychotropics on human BDNF.
Furthermore, it will be interesting to investigate whether
similar effects are also found in peripheral cells of patients
treated with antidepressants. In this regard, it is notewor-
thy that changes in serum concentrations of BDNF after
antidepressant treatments have been measured in a
number of works (as an example, see ref [33]).
Conclusion
The present findings show biphasic changes in the expres-
sion of total and specific BDNF transcripts following anti-
depressant treatments in human cells and encourage the
use of SH-SY5Y cells as a tool for research of psychotropic
drug effects on human genes.
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